These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28813018)

  • 1. Biophysical and Computational Studies of the vCCI:vMIP-II Complex.
    Nguyen AF; Kuo NW; Showalter LJ; Ramos R; Dupureur CM; Colvin ME; LiWang PJ
    Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28813018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into the interaction between a potent anti-inflammatory protein, viral CC chemokine inhibitor (vCCI), and the human CC chemokine, Eotaxin-1.
    Kuo NW; Gao YG; Schill MS; Isern N; Dupureur CM; LiWang PJ
    J Biol Chem; 2014 Mar; 289(10):6592-6603. PubMed ID: 24482230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solution structure of the complex between poxvirus-encoded CC chemokine inhibitor vCCI and human MIP-1beta.
    Zhang L; Derider M; McCornack MA; Jao SC; Isern N; Ness T; Moyer R; LiWang PJ
    Proc Natl Acad Sci U S A; 2006 Sep; 103(38):13985-90. PubMed ID: 16963564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the interactions of vMIP-II, and a dimeric variant of vMIP-II, with glycosaminoglycans.
    Zhao B; Liwang PJ
    Biochemistry; 2010 Aug; 49(33):7012-22. PubMed ID: 20712376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics study on the anti-human immunodeficiency virus chemokine viral macrophage-inflammatory protein-II (VMIP-II) reveals a fully monomeric protein.
    LiWang AC; Cao JJ; Zheng H; Lu Z; Peiper SC; LiWang PJ
    Biochemistry; 1999 Jan; 38(1):442-53. PubMed ID: 9890927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A soluble chemokine-binding protein from vaccinia virus reduces virus virulence and the inflammatory response to infection.
    Reading PC; Symons JA; Smith GL
    J Immunol; 2003 Feb; 170(3):1435-42. PubMed ID: 12538705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
    J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive mapping of poxvirus vCCI chemokine-binding protein. Expanded range of ligand interactions and unusual dissociation kinetics.
    Burns JM; Dairaghi DJ; Deitz M; Tsang M; Schall TJ
    J Biol Chem; 2002 Jan; 277(4):2785-9. PubMed ID: 11696549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structure of viral macrophage inflammatory protein I encoded by Kaposi's sarcoma-associated herpesvirus at 1.7A.
    Luz JG; Yu M; Su Y; Wu Z; Zhou Z; Sun R; Wilson IA
    J Mol Biol; 2005 Oct; 352(5):1019-28. PubMed ID: 16140327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines.
    Dairaghi DJ; Fan RA; McMaster BE; Hanley MR; Schall TJ
    J Biol Chem; 1999 Jul; 274(31):21569-74. PubMed ID: 10419462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR2 and CCR5 receptor-binding properties of herpesvirus-8 vMIP-II based on sequence analysis and its solution structure.
    Shao W; Fernandez E; Sachpatzidis A; Wilken J; Thompson DA; Schweitzer BI; Lolis E
    Eur J Biochem; 2001 May; 268(10):2948-59. PubMed ID: 11358512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kaposi's sarcoma-associated herpesvirus (KSHV)-encoded vMIP-I and vMIP-II induce signal transduction and chemotaxis in monocytic cells.
    Nakano K; Isegawa Y; Zou P; Tadagaki K; Inagi R; Yamanishi K
    Arch Virol; 2003 May; 148(5):871-90. PubMed ID: 12721796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure and function of A41, a vaccinia virus chemokine binding protein.
    Bahar MW; Kenyon JC; Putz MM; Abrescia NG; Pease JE; Wise EL; Stuart DI; Smith GL; Grimes JM
    PLoS Pathog; 2008 Jan; 4(1):e5. PubMed ID: 18208323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient production of fluorophore-labeled CC chemokines for biophysical studies using recombinant enterokinase and recombinant sortase.
    Guan W; Zhang N; Bains A; Sadqi M; Dupureur CM; LiWang PJ
    Biopolymers; 2024 Mar; 115(2):e23557. PubMed ID: 37341434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NMR structures of anti-HIV D-peptides derived from the N-terminus of viral chemokine vMIP-II.
    Mori M; Liu D; Kumar S; Huang Z
    Biochem Biophys Res Commun; 2005 Sep; 335(3):651-8. PubMed ID: 16115468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resonance assignments of the 34 kD rabbitpox vCCI:human MIP-1beta complex.
    Zhang L; Liwang PJ
    J Biomol NMR; 2006; 36 Suppl 1():49. PubMed ID: 16804766
    [No Abstract]   [Full Text] [Related]  

  • 17. The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8.
    Endres MJ; Garlisi CG; Xiao H; Shan L; Hedrick JA
    J Exp Med; 1999 Jun; 189(12):1993-8. PubMed ID: 10377196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct chemotactic and angiogenic activities of peptides derived from Kaposi's sarcoma virus encoded chemokines.
    Benelli R; Barbero A; Buffa A; Aluigi MG; Masiello L; Morbidelli L; Ziche M; Albini A; Noonan D
    Int J Oncol; 2000 Jul; 17(1):75-81. PubMed ID: 10853021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II.
    Chen S; Bacon KB; Li L; Garcia GE; Xia Y; Lo D; Thompson DA; Siani MA; Yamamoto T; Harrison JK; Feng L
    J Exp Med; 1998 Jul; 188(1):193-8. PubMed ID: 9653095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The viral KSHV chemokine vMIP-II inhibits the migration of Naive and activated human NK cells by antagonizing two distinct chemokine receptors.
    Yamin R; Kaynan NS; Glasner A; Vitenshtein A; Tsukerman P; Bauman Y; Ophir Y; Elias S; Bar-On Y; Gur C; Mandelboim O
    PLoS Pathog; 2013 Aug; 9(8):e1003568. PubMed ID: 23966863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.